Category Archives: Scientific publications

The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells, Pauline Estupina et al., Oncotarget February 2017

Oncotarget journal published an article on GamaMabs’12G4 antibody (3C23K precursor).

Pauline Estupina, Alexandre Fontayne, Jean-Marc Barret, Nathalie Kersual, Olivier Dubreuil, Marion Le Blay, Alexandre Pichard, Marta Jarlier, Martine Pugnière, Maëva Chauvin, Thierry Chardès, Jean-Pierre Pouget, Emmanuel Deshayes, Alexis Rossignol, Toufik Abache, Christophe de Romeuf, Aurélie Terrier, Lucie Verhaeghe, Christine Gaucher, Jean-François Prost, André Pèlegrin, Isabelle Navarro-Teulon, (2017) The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells, Oncotarget

AMH_2017_Estupina_Oncotarget

The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer, Nathalie Kersual et al., mAbs October 2014

mAbs journal published an article on GamaMabs’12G4 antibody (3C23K precursor).

Nathalie Kersual, Véronique Garambois, Thierry Chardès, Jean-Pierre Pouget, Imed Salhi, Caroline Bascoul-Mollevi, Frédéric Bibeau, Muriel Busson, Henri Vié, Béatrice Clémenceau, Christian K Behrens, Pauline Estupina, André Pèlegrin & Isabelle Navarro-Teulon (2014) The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer, mAbs, 6:5, 1314-1326

http://dx.doi.org/10.4161/mabs.29316